

LETTER OPEN



ACUTE MYELOID LEUKEMIA

Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial

Inga Hund^{1,2}, Maria Elena Hess^{2,3}, Geoffroy Andrieux³, Julia Stomper^{1,4}, Gabriele Greve^{1,5}, Christoph Niemöller¹, Tobias Ma¹, David Uhl¹, Olga Grishina⁶, Felicitas Thol⁷, Michael Heuser^{7,8}, Gesine Bug⁹, Martina Crysandt⁴, Andreas Neubauer¹⁰, Justus Duyster^{1,11}, Hartmut Döhner¹², Melanie Boerries^{3,11}, Michael Lübbert^{1,11} and Heiko Becker^{1,11}✉

© The Author(s) 2025

Leukemia (2025) 39:2816–2819; <https://doi.org/10.1038/s41375-025-02780-7>

Therapies containing the hypomethylating agents (HMA) decitabine (DEC) or azacitidine (AZA) are standard of care for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. However, initially responsive disease eventually develops secondary resistance [1–4].

Resistance against DEC may result from alterations in pyrimidine metabolism, e.g., deficiency of the DEC-activating deoxycytidine kinase (DCK), or upregulation of the DEC-catabolizing cytidine deaminase or upregulation of SAMHD1, inactivating DEC triphosphate [5–8]. Moreover, expansion of subclones with mutations in signaling proteins may cause secondary resistance [9]. However, for most patients, the resistance-mediating alteration remains elusive.

Here, we investigated acquired resistance after continued DEC treatment in the randomized phase II DECIDER trial.

In this trial, 200 patients received DEC alone or combined with valproic acid (VPA) or all-*trans* retinoic acid (ATRA) or VPA and ATRA [4]. Thirty-five (18%) patients achieved a complete remission (CR), CR without recovery of platelets or neutrophils (CRI), or partial remission (PR); further, 84 (42%) patients had an anti-leukemic effect (ALE) or stable disease (SD). Of these, 14 patients with progressive disease (PD) or relapse after ≥6 months of treatment had samples available from both treatment start and time of PD. Pretreatment characteristics are provided in Supplementary Table S1. Patient selection and methods are described in the Supplementary Data.

All 14 patients received DEC, 8 also received ATRA, and 4 VPA. Six patients achieved CR, CRI or PR as best response, the remainder ALE or SD (Fig. 1). Resistance samples were collected

a median of 10.1 months after treatment initiation (range: 6–64), corresponding to a median of 9 treatment cycles (range: 7–52), including 7 patients with ≥12 cycles (Fig. 1).

We analyzed blasts collected at baseline and at resistance via whole exome sequencing (WES). At baseline, patients harbored a median of 16 mutations (range: 3–25). Most frequently mutated was *RUNX1* ($n = 4$ patients); two patients each harbored mutations in *ASXL1*, *SF3B1*, *SRSF2*, or *TET2*.

At secondary resistance, the overall number of mutations had increased to a median of 36 (range: 6–63), indicating a clonal shift towards resistance. We concentrated on genes known to be cancer-associated (as defined by OncoKB) and on recurrently mutated genes (i.e., acquired in ≥2 patients) (Fig. 2A).

Towards resistance, nine patients had gained at least one mutation in a cancer gene, corresponding to a median of one mutation per patient (range: 0–7). *IDH1* was the only cancer gene that acquired a mutation in more than one patient (p.R132G VAF 5.3%, p.R132H 48%). Further cancer genes mutated in single samples are involved in signaling pathways (e.g., *KIT* VAF 21%, *KRAS* 30%), or transcription (e.g., *GATA2* VAF 45%, *KMT2A* 43%).

Mutations in recurrently mutated genes were acquired in 13 patients, with a median of 2 per patient (range: 0–6). In addition to *IDH1* mutations, mutations in *DCK* (p.S13X VAF 17%, p.R104G VAF 11%) were acquired at resistance in two patients. Further recurrently mutated genes included *SALL3* (VAFs 29%, 22%), *USH2A* (VAFs 36%, 39%), and *TAS2R19*.

TAS2R19 mutations were acquired in five patients at two distinct loci (p.K167E VAF 6.3%, 11%; p.G77S 7.2%, 6.1%, 6.3%). *TAS2R19* has no known function in AML; it is predicted to be involved in G

¹Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

²Faculty of Biology, University of Freiburg, Freiburg, Germany. ³Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ⁴Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. ⁵Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany. ⁶Clinical Trials Unit, Medical Center - University of Freiburg, Freiburg, Germany. ⁷Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

⁸Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany. ⁹Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany. ¹⁰Department of Hematology and Oncology, University Clinic Gießen/Marburg, Marburg, Germany. ¹¹German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany. ¹²Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. ✉email: heiko.becker@uniklinik-freiburg.de

Received: 8 June 2025 Revised: 22 August 2025 Accepted: 23 September 2025

Published online: 7 October 2025




Fig. 1 Treatment and treatment timeline of patients. Depiction of the treatment each patient received and the time on treatment until sampling. Best response indicated per patient. ALE anti-leukemic effect, ATRA all-*trans* retinoic acid, C cycle, CR complete remission, CRi CR without recovery of platelets or neutrophils, DEC decitabine, Maint maintenance, PD progressive disease, PR partial remission, SD stable disease, VPA valproic acid.

protein-coupled receptor signaling pathways and is rarely mutated in cancer (Supplementary Table S2). Recurrence and hotspot location, but not the low VAF, support the functional relevance of these mutations.

Thus, in individual patients, resistance may be linked with mutations in genes with well-established roles in AML or HMA metabolism [5–9]. To our knowledge, ours is the first report to identify mutant *DCK* as potential secondary resistance mechanism in DEC-treated patients. Future studies may investigate whether switch to AZA (activated through uridine-cytidine kinases, not *DCK*) may be beneficial in these patients. In the absence of 2nd line options, mutations in signaling pathways may support the switch to respective inhibitors. Mutant *IDH1* may offer the ready possibility for salvage treatment with an *IDH1* inhibitor.

At secondary resistance, we also observed the loss of a median of six mutations (range: 1–15) per patient compared to baseline. These included mutations in *RUNX1* (baseline VAFs 35%, 99%), *NPM1* (26%), *PPM1D* (12%), and *TP53* (95%) (Fig. 2A).

Given the latter observation and the attention *TP53* receives in the context of DEC [10], we studied *TP53*, including copy number analyses, in greater detail (Supplementary Fig. S2). The *TP53* mutation loss occurred in patient 14 (P14), who was the only patient with mutant *TP53* at baseline and who had a single *TP53* copy at baseline (mutant) and resistance (wild-type). Two other patients (P8, P12) gained *TP53* wild-type alleles towards resistance. Two patients (P9, P10) exhibited bi-allelic *TP53* losses at both baseline and resistance. That patients would rather acquire *TP53* wild-type alleles than *TP53* alterations under long-term DEC treatment is unlikely related to resistance but highlights the unique and incompletely understood impact of DEC on *TP53*-mutant AML clones.

To better comprehend the data, we determined signatures of cancer processes from the WES data (Supplementary Fig. S3) [11]. Among these, signature AC03 was gained towards resistance in nine patients (Fig. 2A, Supplementary Fig. S3). The acquisition correlated with treatment duration and VPA co-treatment,

although not statistically significant (Supplementary Fig. S4). The AC03 gain was also identified in all cell lines with secondary DEC resistance we generated (Supplementary Fig. S5).

AC03 resembles the mutational phenotype of *BRCA1/BRCA2*-mutant cancers, despite lacking these mutations (i.e., BRCAness), due to alternative mechanisms of homologous recombination deficiency [12]. Cancers with BRCAness rely on PARP1 and can be targeted by PARP inhibitors (PARPi). DEC enhances PARP1 chromatin recruitment, synergizing cytotoxicity with PARPi [13]. A phase I trial of DEC plus the PARPi talazoparib (TAL) in AML (22 of 25 patients had prior HMA) showed increased PARP trapping and γH2AX foci in responders [14].

Given the BRCAness at DEC resistance and clinical availability of PARPi, we tested whether cell lines with acquired BRCAness show increased sensitivity to TAL (Supplementary Fig. S6). TAL alone did not induce apoptosis in any tested cell lines, including those with secondary DEC resistance, nor did it increase apoptosis in combination treatments, compared to controls. Solely, in treatment-naïve MOLM13 cells, apoptosis increased with TAL + DEC and TAL + DEC + ATRA (Supplementary Fig. S7). Differentiation marker analyses also revealed no major impact of TAL alone or combined (Supplementary Fig. S6).

The lack of increased PARPi sensitivity suggests that BRCAness after DEC treatment may not stem from HRd. Consistently, BRCAness was not associated with high (>42) HRd scores in patient samples (Supplementary Table S3). While corroboration outside of cell lines (e.g., patient-derived xenograft models) is needed, our results suggest that HMA-induced genomic instability leads to BRCAness (defined by AC03 signature) that may not predict PARPi sensitivity.

We assessed DNA methylation profiles and compared them at resistance to baseline using single-sample analysis (Fig. 2B). A median of 29,264 CpGs (8.9%) were hypomethylated at resistance, whereas hypermethylation was less frequent (median 9853 CpGs, 3%). Consistent with single-sample results, group-wise analysis found 17,854 CpGs (5.4%) significantly hypomethylated at




Fig. 2 Changes in mutation and DNA methylation at secondary resistance. **A** Overview of mutated cancer genes (according to OncoKB) and recurrently mutated genes gained or lost at secondary resistance compared with baseline for each patient. Acquisition of AC03 signature (BRCAness) is indicated in the upper row. VAF, variant allele frequency. **B** Comparative heatmap displaying methylated CpG sites for each patient at treatment start (t1) and resistance (t2). The x-axis represents individual patients, and the y-axis corresponds to CpG sites showing hypomethylation. Patients are grouped by treatment (as indicated). **C** Genomic distribution of differentially methylated CpGs. Hypomethylated sites were annotated based on their genomic context and assessed for their enrichment relative to the overall distribution of these regions in the EPIC array. Enrichment of hypomethylated CpGs of the intergenic region can be seen, as well as depletion of hypomethylation in the TSS200 promoter regions. **D** Identification of shared hypomethylated CpGs across patients. Significant non-random overlap of hypomethylated CpGs (p value 7.03×10^{-9}). Blue lines are random CpGs from the EPIC array, whereas the black lines are CpGs commonly hypomethylated across patients. Of overall 208, 248 hypomethylated CpGs, 21,235 were consistently hypomethylated in >50% of patients. ATRA all-*trans* retinoic acid, DEC decitabine, VPA valproic acid.

resistance, with only two CpGs significantly hypermethylated. This indicates the lasting biologic effect of long-term DEC treatment, persisting even at secondary resistance.

Further analyses revealed no significant correlations between the number of hypo- and hypermethylated CpGs and treatment duration (Supplementary Fig. S8). Analyses of the genomic distribution of differentially methylated CpGs showed a small but significant enrichment in intergenic regions and depletion near the promoter regions (TSS200) (Fig. 2C, Supplementary Fig. S9). We next investigated shared hypo- and hypermethylated CpGs across patients and noted a non-random overlap among hypomethylated CpGs, but not hypermethylated CpGs (Fig. 2D, Supplementary Fig. S9).

Gene set enrichment analysis showed the top 10 most enriched terms for hypomethylated CpGs were related to ion transport or the nervous system (Supplementary Fig. S10). Overactive ion transport in AML is understudied. Among the hypomethylated genes at resistance was *SLC39A10* (zinc transporter ZIP10); blocking ZIP10 decreases AML cell growth and viability [15].

In the DECIDER trial, we observed that adding ATRA delays secondary resistance [4], leading to overrepresentation of

respective patients in our current study. The beneficial impact of ATRA combined with DEC is being further investigated in the DECIDER-2 trial (DRKS00023646). Due to relatively low patient numbers, we could not analyze mutational or methylation differences by DEC combination partners, though ATRA and VPA may impact the molecular underpinnings of resistance development in the individual patient. Despite this, it may even be conceivable that our data can be applied to the current HMA + venetoclax standard, but future studies are required to confirm this.

Our study is the first to provide extensive genetic and DNA methylation data on AML patients with secondary resistance after prolonged HMA treatment. While no universal gene or pathway was linked to resistance, individual patients acquired mutations with biological or clinical relevance (e.g., in *DCK*, *IDH1*, or signaling genes). In addition, we observed BRCAness emerging in most patients, likely rather as product of continued DEC treatment than driving resistance, and not sensitizing to PARPi in cell lines. DNA methylation profiling identified CpGs differentially methylated between baseline and resistance, comprising almost exclusively hypomethylated CpGs at resistance. Persistent and non-random

DNA hypomethylation at resistance may inform future treatment approaches.

DATA AVAILABILITY

Due to ethical and legal considerations, patient data from this study cannot be shared publicly. Qualified researchers may request access to anonymized data by contacting heiko.becker@uniklinik-freiburg.de and providing a detailed data access proposal, subject to approval by the relevant ethics committee.

REFERENCES

- Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. *Haematologica*. 2012;97:393–401.
- Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J Clin Oncol*. 2012;30:2670–7.
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*. 2020;383:617–29.
- Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 × 2, phase II trial. *J Clin Oncol*. 2020;38:257–70.
- Stegmann AP, Honders MW, Willemze R, Landegent JE. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC). *Leukemia*. 1995;9:1032–8.
- Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. *Leukemia*. 2021;35:1023–36.
- Wu B, Mao ZJ, Wang Z, Wu P, Huang H, Zhao W, et al. Deoxycytidine kinase (dck) mutations in human acute myeloid leukemia resistant to cytarabine. *Acta Haematol*. 2021;144:534–41.
- Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. *Nat Commun*. 2019;10:3475.
- Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, et al. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. *Br J Haematol*. 2018;182:830–42.
- Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, et al. Impact of TP53 mutation status in elderly AML patients when adding all-trans retinoic acid or valproic acid to decitabine. *Eur J Haematol*. 2025;114:231–7.
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature*. 2013;500:415–21.
- Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsaw G, Fröhlich M, et al. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. *Nat Commun*. 2019;10:1635.
- Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents—a potential therapy for cancer. *Cancer Cell*. 2016;30:637–50.
- Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, et al. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia. *Clin Cancer Res*. 2022;28:1313–22.
- Rolles B, Chatain N, Görg R, Vierl M, Tillmann-Tröster N, Bourgeois MG, et al. ZIP10 as a potential therapeutic target in acute myeloid leukaemia. *Br J Haematol* 2025; <https://doi.org/10.1111/bjh.20229>.

ACKNOWLEDGEMENTS

The research was supported by the German Research Foundation (DFG): FOR 2674 A05 BE 6461/1-2 (to HB), LU 429/16-2 (to ML), FOR 2674 A02 (to HD), CRC1160 Project ID 256073931-Z02 (to MB), CRC/TRR167 Project ID 259373024-Z01 (to MB), CRC1453

Project ID 431984000-S1 (to MB), CRC1479 Project ID 441891347- S1 (to MB), TRR 359 Project ID 491676693-Z01 (to M.B.), TRR 353 Project ID 471011418-SP02 (to MB), FOR 5476 UcarE Project ID 493802833-P7 (to MB), the German José Carreras Leukemia-Foundation 17R/2019 (to HB) and AH06-01 (to AN), the German Consortium for Translational Cancer Research (DKTK) (to ML) and the German Federal Ministry of Education and Research (BMBF) NanodiagBW P3 (to HB), PM4Onco-FKZ 01ZZ2322A (to MB) and EkoEstMed-FKZ 01ZZ2015 (to GA). The Lighthouse Core Facility is funded in part by the Medical Faculty, University of Freiburg (Project Number 2023/B3-Fol).

AUTHOR CONTRIBUTIONS

IH, ML, HB undertook conception and design of the study; IH, CN, DU performed molecular and cellular experiments; MEH, GA, JS, MB developed computational pipelines and analyzed the data; JD, MB, ML, and HB provided conceptual advice; JD, MB, ML, and HB secured funding and supervised the work. GG, TM performed specimen acquisition and processing; OG, FT, MH, GB, MC, AN, HD, ML, HB were responsible for treatment of patients and specimen acquisition; IH, ML, HB wrote the manuscript. All authors accepted the final version of the manuscript.

FUNDING

Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS

HB: honoraria from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre Pharma, and Servier. HD: consultancy (AdBoard) with honoraria from AbbVie, Otsuka, Pfizer, Servier, Syndax; and clinical research funding to the institution from AbbVie, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Servier; and travel/ accommodation expenses from AbbVie, Servier. The remaining authors declare that they have no competing interests.

ETHICS APPROVAL

All study methods were performed in accordance with relevant guidelines and regulations. Ethics approval was obtained from the Ethics Committee at the University of Freiburg (76/10-120689). Written informed consent was obtained from all subjects.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-025-02780-7>.

Correspondence and requests for materials should be addressed to Heiko Becker.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025